Sector News

Positive opinion for Novo Nordisk’s Sogroya

May 27, 2023
Life sciences

Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has provided a positive opinion for the company’s Sogroya therapy.

The once-weekly treatment – also known as somapacitan – is for the replacement of endogenous growth hormone (GH) in aged children three years and older. It can also be used to treat adolescents with growth failure due to growth hormone deficiency.

The positive opinion has emerged following data from Novo Nordisk’s phase 3 ‘REAL4’ trial, which demonstrated that a once-weekly subcutaneous injection of Sogroya worked as effectively as a daily injection of Norditropin.

By the conclusion of the trial period, prepubertal children who were treated with once-weekly Sogroya had achieved similar growth as children who were treated with Norditropin.

Martin Holst Lange, executive vice president for development at Novo Nordisk, was optimistic about the verdict: “Today’s positive CHMP opinion is a step forward to reducing the impact of growth hormone deficiency for children, adolescents and their families in Europe.”

He added: “We are hopeful that Sogroya will help improve the lives of children as young as three years old by offering a simpler treatment option with fewer injections in an easy-to-use device, whilst helping them to achieve their growth targets.”

Meanwhile, the European Commission (EC) will review the CHMP’s positive opinion and a final decision on marketing authorisation is expected later in the year. If approved, Sogroya will be available across some European countries by the end of 2023.

Growth hormone deficiency is a rare disease and a treatable cause of short stature – it is thought to impact around one in 3,500 to 10,000 children.

by John Pinching


comments closed

Related News

June 8, 2024

Lilly CFO leaves to join Alphabet

Life sciences

Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior vice president of Google and Alphabet. Ashkenazi has been CFO at Lilly since 2021 and originally joined the company in 2001. Over her 23-year career at the Indianapolis-based drugmaker, Ashkenazi also served as controller, CFO of Lilly Research Laboratories and as the finance chief for several global divisions within the company.

June 8, 2024

Edwards Lifesciences to cell Critical Care to BD

Life sciences

Edwards Lifesciences (NYSE: EW) announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.

June 8, 2024

Danaher names Martin Stumpe as chief data and AI officer

Life sciences

The company, which owns diagnostics and life sciences businesses including Beckman Coulter and Cepheid, said the appointment reflects its increasing investment in AI as “a driving force for innovation and productivity.” Danaher is focused on AI by also spending on its internal capabilities and partnering with academic groups.

How can we help you?

We're easy to reach